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Clinical vignette 
A 38 year-old male with a history of end-
stage renal disease from IgA nephropathy 
underwent kidney transplantation a year ago 
and is currently on immunosuppressive 
medications. He presents with diarrhea and 
dehydration. A molecular “gastrointestinal 
panel” for 22 targets was ordered and the 
results came back negative. This panel does 
NOT include which of the following 
potential etiologic agents in this patient? 
a. Giardia 
b. Cryptosporidium 
c. Cystoisospora 
d. Cyclospora 
e. Entamoeba 
 
This commercially available gastrointestinal 
panel does not include Cystoisospora and 
microsporidia, which are also in the 
differential diagnosis for this 
immunocompromised patient. Clinicians 
need to order tests for these organisms 
separately.  
 
Key recommendations from the 2017 
Infectious Diseases Society of America 
Clinical Practice Guidelines for the 
Diagnosis and Management of Infectious 
Diarrhea 
1. A detailed clinical and exposure history 
should be obtained from people with 
diarrhea, under any circumstances, 
including when there is a history of 
similar illness in others. 
2. People with fever or bloody diarrhea 
should be evaluated for enteropathogens 
for which antimicrobial agents may 
confer clinical benefit, including 
Salmonella enterica subspecies, Shigella, 
and Campylobacter. 
3. Enteric fever should be considered when 
a febrile person (with or without diarrhea) 
has a history of travel to areas in which 
causative agents are endemic, or has 
consumed foods prepared by people with 
recent endemic exposure. 
4. People of all ages with acute diarrhea 
should be evaluated for dehydration. 
5. When the clinical or epidemic history 
suggests a possible Shiga toxin-
producing organism, diagnostic 
approaches should be applied that detect 
Shiga toxin (or the genes that encode 
them). It is important to distinguish 
Escherichia coli O157:H7 from other 
Shiga toxin-producing E. coli (STEC) in 
stool. In addition, Shigella dysenteriae 
type 1 and, rarely, other pathogens may 
produce Shiga toxin and should be 
considered as a cause of hemolytic 
uremic syndrome (HUS).  
6. Stool testing should be performed for 
Salmonella, Shigella, Campylobacter, 
Yersinia, C. difficile, and STEC in people 
with diarrhea accompanied by fever, 
bloody or mucoid stools, severe 
abdominal cramping or tenderness, or 
signs of sepsis. Blood cultures should be 
obtained from people with signs of sepsis, 
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with immunocompromising condition, or 
when enteric fever is suspected. 
7. A broad differential diagnosis is 
recommended in immunocompromised 
people with diarrhea. Additional testing 
may include Cryptosporidium, 
Cyclospora, Cystoisospora, 
microsporidia, Mycobacterium avium 
complex, and cytomegalovirus.   
8. Diagnostic testing is not recommended in 
most cases of uncomplicated traveler’s 
diarrhea unless treatment is indicated.  
9. The optimal specimen for laboratory 
diagnosis of infectious diarrhea is a 
diarrheal stool sample (i.e. a sample that 
takes the shape of the container). 
10. Fecal leukocyte examination and stool 
lactoferrin detection should not be used to 
establish the cause of an acute infectious 
diarrhea.  
11. Follow-up testing is not recommended in 
most people for case management 
following resolution of diarrhea.  
12. Noninfectious conditions, including IBD 
and IBS, should be considered as 
underlying etiologies in people with 
symptoms lasting 14 or more days and 
unidentified sources. 
13. Empiric therapy for the 
immunocompetent adults with bloody 
diarrhea is not recommended except for 
people with fever documented in a 
medical setting, abdominal pain, bloody 
diarrhea, and bacillary dysentery 
(frequent scant bloody stools, fever, 
abdominal cramps, tenesmus) 
presumptively due to Shigella; or for 
people who have travelled internationally 
with body temperatures ≥ 38.5˚C, and/ or 
signs of sepsis who are suspected of 
having enteric fever.  
14. Empiric antibacterial treatment should be 
considered in the immunocompromised 
people with severe illness and bloody 
diarrhea. 
15. Antimicrobial therapy for people with 
infections attributed to STEC O157 and 
other STEC that produce Shiga toxin 2 
should be avoided.  
16. The empiric antimicrobial therapy in 
adults should be either a fluoroquinolone 
such as ciprofloxacin, or azithromycin, 
depending on the local susceptibility 
patterns and travel history. 
17. In most people with acute watery diarrhea 
and without recent international travel, 
empiric antimicrobial therapy is not 
recommended, with the exception of 
people who are immunocompromised.  
18. Empiric therapy should be avoided in 
people with persistent watery diarrhea 
lasting 14 days or more.  
19. Antimotility drugs should be avoided in 
suspected or proven cases where toxic 
megacolon may result in inflammatory 
diarrhea with fever.  
20. Probiotic preparations may be offered to 
reduce the symptom severity and duration 
in immunocompetent adults with 
infectious or antimicrobial-associated 
diarrhea.  
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